A job opportunity is available to join a project related to the FINE-ONE trial, a phase 3 clinical trial funded by Bayer. The trial investigated the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in adults with Type 1 diabetes and chronic kidney disease (CKD).
Job Overview
The role involves working on the FINE-ONE trial (NCT05901831), which was a double-blind, randomised, placebo-controlled study conducted across multiple sites.
Eligibility Criteria
- Candidates must be adults.
- Confirmed diagnosis of Type 1 diabetes.
- Chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) between 25 and less than 90 ml per minute per 1.73 m².
- Albuminuria measured as a urinary albumin-to-creatinine ratio (UACR) of between 200 and less than 5,000.
- Crucially, all participants had to already be receiving either an ACE inhibitor or an angiotensin-receptor blocker.
Selection Process
- Enrollment was limited to adults meeting a specific and demanding set of criteria.
- A total of 242 adults were randomised.
- Those assigned to the treatment arm received finerenone at either 10 mg or 20 mg per day, with the dose determined by their kidney function.
- Those in the control arm received a matching placebo.
Conclusion
The trial found that finerenone produces a significantly greater reduction in a key marker of kidney damage compared to placebo in adults with Type 1 diabetes and chronic kidney disease (CKD). Eligible individuals interested in this field may find this relevant.
